ECSP22016630A - Métodos sintéticos mejorados para la elaboración de compuestos de (2h-1,2,3-triazol-2-il)fenilo como moduladores del receptor de orexina - Google Patents

Métodos sintéticos mejorados para la elaboración de compuestos de (2h-1,2,3-triazol-2-il)fenilo como moduladores del receptor de orexina

Info

Publication number
ECSP22016630A
ECSP22016630A ECSENADI202216630A ECDI202216630A ECSP22016630A EC SP22016630 A ECSP22016630 A EC SP22016630A EC SENADI202216630 A ECSENADI202216630 A EC SENADI202216630A EC DI202216630 A ECDI202216630 A EC DI202216630A EC SP22016630 A ECSP22016630 A EC SP22016630A
Authority
EC
Ecuador
Prior art keywords
triazol
elaboration
orexin receptor
synthetic methods
receptor modulators
Prior art date
Application number
ECSENADI202216630A
Other languages
English (en)
Inventor
Florian Damien Medina
Dominique Paul Michel Depre
Pieter Westerduin
Cheng Yi Chen
Kiran Matcha
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72139573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP22016630(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP22016630A publication Critical patent/ECSP22016630A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/74—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/76—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/16—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of hydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/74—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/78—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/30—Nitrogen atoms non-acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen procesos para preparar (((3aR,6aS)-5-(4,6-dimetilpirimidin-2-il)hexahidropirrolo[3,4-c]pirrol-2(1H)-il)(2-fluoro-6-(2H-1,2,3-triazol-2-il)fenil)metanona, que son útiles para la fabricación comercial. Dicho compuesto es un modulador del receptor de orexina y puede ser útil en composiciones farmacéuticas y métodos para el tratamiento de estados de enfermedad, trastornos y afecciones mediadas por la actividad de la orexina, tales como el insomnio y la depresión.
ECSENADI202216630A 2019-08-07 2022-03-04 Métodos sintéticos mejorados para la elaboración de compuestos de (2h-1,2,3-triazol-2-il)fenilo como moduladores del receptor de orexina ECSP22016630A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962883857P 2019-08-07 2019-08-07
US202062971265P 2020-02-07 2020-02-07

Publications (1)

Publication Number Publication Date
ECSP22016630A true ECSP22016630A (es) 2022-04-29

Family

ID=72139573

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202216630A ECSP22016630A (es) 2019-08-07 2022-03-04 Métodos sintéticos mejorados para la elaboración de compuestos de (2h-1,2,3-triazol-2-il)fenilo como moduladores del receptor de orexina

Country Status (16)

Country Link
US (1) US12570658B2 (es)
EP (1) EP4010325A1 (es)
JP (1) JP7672386B2 (es)
KR (1) KR20220044323A (es)
CN (2) CN120097862A (es)
AU (1) AU2020324552A1 (es)
BR (1) BR112022002128A2 (es)
CA (1) CA3149689A1 (es)
CR (1) CR20220050A (es)
EC (1) ECSP22016630A (es)
IL (1) IL290362A (es)
JO (1) JOP20220031A1 (es)
MX (1) MX2022001615A (es)
PE (1) PE20220842A1 (es)
PH (1) PH12022550295A1 (es)
WO (1) WO2021023843A1 (es)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2258276C3 (de) 1972-11-28 1981-08-13 Bayer Ag, 5090 Leverkusen Triazolyl-stilbene, sowie deren Herstellung und Verwendung als optische Aufheller
US4826833A (en) * 1984-01-30 1989-05-02 Pfizer Inc. 6-(Substituted)methylene-penicillanic and 6-(substituted)hydroxymethylpenicillanic acids and derivatives thereof
DE4341403A1 (de) 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
MY145722A (en) 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
WO2006124897A2 (en) 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Methods and compositions for improving cognition
CN101193635A (zh) 2005-05-13 2008-06-04 莱西肯医药有限公司 多环化合物及其使用方法
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
US20080153811A1 (en) 2006-11-07 2008-06-26 Joseph Barbosa Methods of Treating Cognitive Impairment and Dementia
CN101952286A (zh) 2007-12-21 2011-01-19 阿斯利康(瑞典)有限公司 用于治疗和雄激素受体有关的病症的双环衍生物
ME03452B (me) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
EP2491031B1 (en) 2009-10-23 2013-08-07 Janssen Pharmaceutica N.V. Fused heterocyclic compounds as orexin receptor modulators
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
DK2903440T3 (en) 2012-10-02 2017-12-11 Bayer Cropscience Ag THETEROCYCLIC COMPOUNDS AS PESTICIDES
CN103012293A (zh) 2012-12-13 2013-04-03 同济大学 一种抗失眠药物mk-4305中间体的合成方法
MX393838B (es) 2014-04-01 2025-03-21 Bayer Cropscience Ag Uso de compuestos heterociclicos para controlar nematodos.
US9938276B2 (en) 2014-12-19 2018-04-10 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
WO2016171248A1 (ja) 2015-04-24 2016-10-27 武田薬品工業株式会社 複素環化合物
KR20230116948A (ko) 2016-03-10 2023-08-04 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법
GB201702174D0 (en) 2017-02-09 2017-03-29 Benevolentai Bio Ltd Orexin receptor antagonists
JP2025083724A (ja) 2023-11-21 2025-06-02 日東精工株式会社 電動ドライバ

Also Published As

Publication number Publication date
MX2022001615A (es) 2022-05-26
PE20220842A1 (es) 2022-05-24
CA3149689A1 (en) 2021-02-11
IL290362A (en) 2022-04-01
CR20220050A (es) 2022-04-20
CN120097862A (zh) 2025-06-06
JOP20220031A1 (ar) 2023-01-30
CN114555603B (zh) 2025-03-14
US12570658B2 (en) 2026-03-10
EP4010325A1 (en) 2022-06-15
AU2020324552A1 (en) 2022-03-24
KR20220044323A (ko) 2022-04-07
PH12022550295A1 (en) 2022-11-21
WO2021023843A1 (en) 2021-02-11
JP7672386B2 (ja) 2025-05-07
BR112022002128A2 (pt) 2022-06-07
JP2022543286A (ja) 2022-10-11
CN114555603A (zh) 2022-05-27
US20220289754A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
ECSP21034253A (es) Métodos sintéticos mejorados para elaborar compuestos heterocíclicos fusionados como moduladores del receptor de orexina
ECSP19047936A (es) Imidazopirrolopiridina como inhibidores de la familia de quinasas jak
SV2018005800A (es) Moduladores alostéricos positivos del receptor muscarínico de acetilcolina m4
CR20120273A (es) OCTAHIDROPIRROLO[3,4-c]PIRROLOS DISUSTITUIDOS COMO MODULADORES DEL RECEPTOR DE OREXINA
ECSP19042688A (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak
BR112016000195A8 (pt) compostos heterocíclicos, composição farmacêutica, combinação, seu uso, e método para inibir uma atividade da tirosina quinase btk ou jak, egfr, alk, pdgfr, blk, bmx/etk, flt3(d835y), itk, tec, txk, e suas respectivas vias
EP2576549A4 (en) Bicyclic Heteroarylkinase Inhibitors and Methods of Use
UY32967A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de la orexina
EA201790995A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
MX2020012097A (es) Proceso para preparar inhibidores de tirosina cinasa de bruton (btk).
CO2021016860A2 (es) Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b
CL2021001547A1 (es) Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer
NI202000100A (es) Inhibidores de moléculas pequeñas de la familia de quinasa jak
MX2023004942A (es) Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades.
CR20220050A (es) Métodos sintéticos mejorados para la elaboración de compuestos de (2h-1,2,3-triazol-2-il)fenilo como moduladores del receptor de orexina
MX2022011310A (es) Azabiciclo y derivados de diazepina para tratar trastornos oculares.
CL2024001748A1 (es) Usos de compuestos biciclicos para el tratamiento de enfermedades.
MX2024005997A (es) Antagonistas del receptor de adenosina.
De Grandis Abnormal adhesion of red blood cells in polycythemia vera: role of the jak2V617f mutation and impact of hydroxycarbamide and interferon-α treatments
CR20190283A (es) Imidazopyrrolopyridine as inhibitors of the jak family of kinases
AR133852A2 (es) Sales de un inhibidor de pim quinasa